ENTX

Latest SEC Filings & News for ENTX

2 most recent filings and news items mentioning ENTX. Updated every 60 seconds.

Get this data via API — free tier: 10,000 calls/day

curl "https://api.brieftape.com/v1/tickers/ENTX/news?limit=20"

Pull ENTX filings straight into your trading bot, model, or app.

Get an API key — free tier: 10,000 calls/day

Regulation|OfferingAug 7, 2026Neutral

Entera Bio Reaches FDA Alignment on EB613 Phase 3 Study to Support NDA

Entera Bio Ltd. announced positive FDA feedback for a Phase 3 osteoporosis study and a $275 million private placement, fortifying the company's financial ability to advance core assets.

View filing at SEC.gov →

RegulatoryMay 18, 2026Positive

Entrada Therapeutics presents Phase 1/2 DMD trial data for ENTR-601-44.

Entrada shared a corporate presentation on its ENTR-601-44 candidate in Duchenne muscular dystrophy, outlining expectations for open-label period completion by end-2026 and multiple dose cohorts with escalating exposure. The presentation contains forward-looking statements about

View filing at SEC.gov →

AI-summarized public filings for informational purposes only. Not investment advice. Always verify against the original filing at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.